Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14197667 | 0.79 | TSHR (0.42) | MAPK1TSHRHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL27854511 | 0.79 | MAPK1 (0.46) | MAPK1TSHRHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL14197401 | 0.77 | MAPK1 (0.40) | MAPK1TSHRHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL11748265 | 0.73 | IDO1 (0.56) | MAPK1TSHRHSD17B10MEN1KMT2A | |
| SCHEMBL13708865 | 0.72 | MAPK1 (0.45) | MAPK1TSHRHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL1060629 | 0.72 | L3MBTL1 (0.67) | MAPK1HSD17B10SMN1; SMN2MEN1KMT2A | |
| SCHEMBL9232260 | 0.71 | HSD17B10 (0.45) | HSD17B10LMNA | |
| SCHEMBL11256989 | 0.70 | APEX1 (0.79) | MAPK1TSHRHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL12962917 | 0.70 | NPC1 (0.45) | MAPK1TSHRHSD17B10SMN1; SMN2MEN1 | |
| SCHEMBL27890324 | 0.69 | IDO1 (0.61) | KMT2AGLAKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | MAPK1 3908/4885TSHR 1761/4885HSD17B10 1450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.